Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving p53MVA and pembrolizumab together may work better in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To assess response rate (complete responses and partial responses) after treatment with p53MVA and pembrolizumab. SECONDARY OBJECTIVE: I. To assess median progression free survival (PFS), clinical benefit (complete response, partial response lasting > 6 months), overall survival (OS), safety and tolerability. EXPLORATORY OBJECTIVE: I. Evaluate if the CD8+ T cell signal exceeds that detected in the single agent p53MVA trial. OUTLINE: This is a dose-escalation study of modified vaccinia virus ankara vaccine expressing p53. Patients receive pembrolizumab intravenously (IV) over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 subcutaneously (SC) every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1-3 weeks and every 12 weeks thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03113487
Study type Interventional
Source City of Hope Medical Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 1, 2018
Completion date August 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05691504 - Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Phase 1
Active, not recruiting NCT05026606 - Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 2
Recruiting NCT05231122 - Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Phase 2
Withdrawn NCT05295589 - Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Phase 2
Active, not recruiting NCT02839707 - Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2/Phase 3
Not yet recruiting NCT06393751 - Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2
Active, not recruiting NCT04739800 - Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Phase 2
Recruiting NCT04633239 - Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer Phase 1
Recruiting NCT04840589 - Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors Phase 1